Personalized Polygala Extract-Based Systems for Attention-Deficit Hyperactivity Disorder Treatment

This inventive concept envisions a next-generation approach to treating attention-deficit hyperactivity disorder (ADHD) by leveraging cutting-edge technologies, such as wearable devices, genetic profiling, nanodelivery systems, and machine learning algorithms, to provide personalized and targeted treatment solutions.

The original patent disclosed a method for treating ADHD using a composition comprising a Radix Polygalae extract. However, this approach has limitations, including the need for manual administration, lack of real-time monitoring, and limited customization. The new inventive concept addresses these limitations by introducing a range of innovative solutions that can adapt to individual patients' needs and brain activity.

The inventive concept comprises five key components: (1) a wearable device that administers a customized dosage of a Polygala extract composition based on real-time brain activity monitoring; (2) a method for predicting ADHD symptom onset by analyzing a subject's genetic profile and environmental factors; (3) a Polygala extract-based nanodelivery system for targeted treatment of ADHD; (4) a personalized Polygala extract treatment plan generation system using machine learning algorithms; and (5) a transdermal patch for delivering a Polygala extract composition with programmable dosage and release rate adjustment. These components work together to provide a comprehensive and adaptive treatment approach.

The new claims introduce a paradigm shift in ADHD treatment by integrating advanced technologies and data-driven approaches. The inventive concept's novelty lies in its ability to provide real-time monitoring, personalized treatment, and targeted delivery, which are not addressed by the original patent.

Alternative embodiments of the inventive concept could include using other botanical extracts or combining Polygala extract with other therapeutics. Variations could include using different types of wearable devices, such as implantable sensors or smart clothing, or integrating the treatment system with other health monitoring platforms.

The inventive concept has significant commercial potential in the ADHD treatment market, which is expected to grow substantially in the coming years. The targeted and personalized approach could also expand into other neurological disorders, such as anxiety and depression, and potentially disrupt the traditional pharmaceutical industry.